BBOT (STOCKS)
BridgeBio Oncology Therapeutics, Inc. Common Stock
$9.120000
+0.720000 (+8.57%)
Prev close: $8.400000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Eli M. Wallace
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $715.49M
- Employees
- 92
- P/E (TTM)
- -5.98
- P/B (TTM)
- 1.63
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $11.78M |
| Operating Expenses | $145.82M |
| Research and Development | $121.20M |
| Other Operating Expenses | $24.62M |
| Operating Income/Loss | -$145.82M |
| Income/Loss From Continuing Operations After Tax | -$134.04M |
| Income/Loss From Continuing Operations Before Tax | -$134.04M |
| Income Tax Expense/Benefit | $0.00 |
| Income Tax Expense/Benefit, Current | $0.00 |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$134.04M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$134.04M |
| Net Income/Loss Available To Common Stockholders, Basic | -$134.04M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.30 |
| Diluted Earnings Per Share | -$4.30 |
| Basic Average Shares | 31,144,775 |
| Diluted Average Shares | 31,144,775 |
| Assets | $448.38M |
| Current Assets | $432.40M |
| Cash | $425.50M |
| Other Current Assets | $6.90M |
| Noncurrent Assets | $15.99M |
| Fixed Assets | $956.00K |
| Other Non-current Assets | $15.03M |
| Liabilities | $37.29M |
| Current Liabilities | $35.04M |
| Accounts Payable | $1.37M |
| Other Current Liabilities | $33.67M |
| Noncurrent Liabilities | $2.24M |
| Equity | $411.10M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $411.10M |
| Liabilities And Equity | $448.38M |
| Net Cash Flow From Operating Activities | -$113.89M |
| Net Cash Flow From Operating Activities, Continuing | -$113.89M |
| Net Cash Flow From Investing Activities | $73.33M |
| Net Cash Flow From Investing Activities, Continuing | $73.33M |
| Net Cash Flow From Financing Activities | $383.40M |
| Net Cash Flow From Financing Activities, Continuing | $383.40M |
| Net Cash Flow | $342.84M |
| Net Cash Flow, Continuing | $342.84M |
| Comprehensive Income/Loss | -$134.38M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$134.38M |
| Other Comprehensive Income/Loss | -$134.38M |